Wyeth mulls global sales force restructuring

Share this article:
Wyeth said the restructuring of its U.S. sales force was only a start and that it is considering making similar changes globally.
"Obviously it is a first step. We're also looking internationally. Our European affiliates have started to look at how to optimize the sales force," said Bernard Poussot, head of Wyeth's pharmaceutical operations said in a Financial Times report.
Last month, Wyeth said it would use inside, part-time sales representatives in the U.S. to complement its full-time sales force, which is being reduced by about 25 percent to 30 percent.
Adding the part-timers will result in a net sales force reduction of about 15 percent, Poussot said.
Wyeth has deployed part-timers in its consumer division for the past few years.
As reported in MM&M, the drug maker began piloting them in its pharmaceuticals division in July and said it will fully implement them by year's end (MM&M, July 2005).
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union